Confusable diagnoses · PANCE / PANRE

Type 1 Diabetes Mellitus vs Type 2 Diabetes Mellitus

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus are easy to mix up on the boards. Here's a side-by-side comparison — presentation, workup, imaging, and first-line treatment — drawn from our full outlines.

Type 1 Diabetes Mellitus vs Type 2 Diabetes Mellitus at a glance

  • Type 1 Diabetes Mellitus: Autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency.
  • Type 2 Diabetes Mellitus: Insulin resistance with progressive beta-cell dysfunction; most common form of diabetes.

Try two board-style questions on Type 1 Diabetes Mellitus vs Type 2 Diabetes Mellitus

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1EndocrineMedium
A 14-year-old previously healthy boy presents with polyuria, polydipsia, weight loss, and fruity breath. Labs: glucose 480 mg/dL, anion gap 22, beta-hydroxybutyrate elevated. He is positive for GAD-65 and islet cell antibodies. Which mechanism best explains his disease?
  • AAutoimmune destruction of pancreatic beta cells
  • BMitochondrial dysfunction in muscle and liver
  • CPeripheral insulin resistance
  • DImpaired incretin (GLP-1) signaling
Reveal answer & full explanation
Correct answer: A — Autoimmune destruction of pancreatic beta cells
  • AAutoimmune destruction of pancreatic beta cells✓
  • BMitochondrial dysfunction in muscle and liver
  • CPeripheral insulin resistance
  • DImpaired incretin (GLP-1) signaling

Why Autoimmune destruction of pancreatic beta cells is correct

  • Type 1 diabetes is caused by autoimmune T-cell mediated destruction of pancreatic beta cells, producing absolute insulin deficiency
  • Autoimmune markers include anti-glutamic acid decarboxylase (anti-GAD-65), islet cell antibodies (ICA), insulin autoantibodies (IAA), and IA-2 antibodies
  • Genetic associations: HLA-DR3/DR4
  • Patients are typically lean, present with diabetic ketoacidosis (DKA), and require lifelong insulin

Why the others are wrong

  • Mitochondrial dysfunction in muscle and liver — Mitochondrial dysfunction is associated with mitochondrial diabetes (e.g., MELAS syndrome), not autoimmune type 1 DM
  • Peripheral insulin resistance — Peripheral insulin resistance and progressive beta-cell dysfunction in the setting of obesity characterize type 2 diabetes mellitus (DM)
  • Impaired incretin (GLP-1) signaling — A blunted incretin effect contributes to hyperglycemia in type 2 DM and is the target of GLP-1 receptor agonists, but it does not destroy beta cells and cannot produce islet autoantibodies or the absolute insulin deficiency driving DKA here

Additional high-yield points

  • Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes with various mutations and should be distinguished from type 1 DM
Question 2EndocrineEasy
A 48-year-old man with a BMI of 32 kg/m2 is newly diagnosed with type 2 diabetes mellitus after a fasting glucose of 215 mg/dL and a hemoglobin A1c of 9.2%. He has no atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, and no contraindication to oral agents. Which of the following is the most appropriate first-line pharmacotherapy?
  • AInsulin glargine
  • BMetformin
  • CSitagliptin
  • DGlipizide
Reveal answer & full explanation
Correct answer: B — Metformin
  • AInsulin glargine
  • BMetformin✓
  • CSitagliptin
  • DGlipizide

Why Metformin is correct

  • For type 2 diabetes without compelling cardiorenal indications, metformin remains the recommended first-line glucose-lowering agent per current ADA Standards of Care.
  • It lowers hepatic glucose output, is weight-neutral, carries low hypoglycemia risk, and is inexpensive.
  • A second agent is layered on if the A1c goal is not met after about 3 months.

Why the others are wrong

  • Insulin glargine — initial insulin is reserved for very high A1c (typically >10%), catabolic symptoms, or oral-agent failure, none of which apply, making it a premature-closure overreach for a glucose of 215 mg/dL.
  • Sitagliptin — a DPP-4 inhibitor lowers A1c only about 0.5-0.8%, is weight-neutral, and confers no cardiorenal benefit, so it is an add-on agent rather than preferred initial monotherapy, least of all at an A1c of 9.2%; the right-idea-wrong-agent trap.
  • Glipizide — sulfonylureas cause weight gain and hypoglycemia and are not preferred initial monotherapy, the right-class-wrong-choice trap.

Additional high-yield points

  • Current ADA Standards no longer make metformin automatic for every patient: when weight management is a major treatment goal, an agent with high weight-loss efficacy such as semaglutide or tirzepatide may be chosen as initial therapy, and an A1c 1.5-2.0% or more above goal supports starting combination therapy from the outset.
  • Metformin's limits are eGFR-based: it is contraindicated below an eGFR of 30 mL/min/1.73 m2 and should not be initiated between 30 and 45.
🔒 Free preview limit reached

Keep comparing — start your free trial

You've used your 2 free previews. Create your free account to see the full Type 1 Diabetes Mellitus vs Type 2 Diabetes Mellitus comparison — plus all 514 diagnosis outlines, 7,200+ board-style questions, and an AI tutor. Your 7-day free trial includes everything, no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Side-by-side comparison

FeatureType 1 Diabetes MellitusType 2 Diabetes Mellitus
At a glanceAutoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency.Insulin resistance with progressive beta-cell dysfunction; most common form of diabetes.
Classic presentationLean young patient with rapid onset of polyuria, polydipsia, weight loss, sometimes presenting in DKA.; Classic triad: polyuria, polydipsia, polyphagia; Unintentional weight loss despite normal or increased intake; Fatigue, weakness, blurred vision; May present with DKA as initial manifestation (~30% of pediatric cases): nausea,…Acanthosis nigricans on the posterior neck in an overweight adult is a classic sign of insulin resistance.; Often asymptomatic; diagnosed on screening labs; Polyuria, polydipsia, polyphagia (less prominent than T1DM); Fatigue, blurred vision, slow wound healing; Recurrent infections (yeast, UTI, skin); May present with complications:…
Workup / key labsADA criteria: A1c ≥6.5%, fasting glucose ≥126 mg/dL, 2-hr OGTT ≥200 mg/dL, or random ≥200 mg/dL with symptoms. T1DM confirmed by positive autoantibodies and/or low C-peptide. With acute symptomatic onset, use plasma glucose rather than A1c, which lags rapidly rising glucose. Staging: stage 1 = ≥2 islet autoantibodies with normal…A1c ≥6.5%, fasting glucose ≥126 mg/dL (8-hr fast), 2-hr OGTT ≥200 mg/dL (75 g load), or random ≥200 mg/dL with symptoms. Prediabetes: A1c 5.7-6.4%, fasting 100-125, OGTT 140-199.; Screening: USPSTF recommends screening adults 35-70 with overweight/obesity; ADA recommends starting at age 35 for all, earlier with risk factors; A1c ≥6.5%,…
ImagingNot routinely needed for diagnosis; Dilated eye exam 5 years after diagnosis in adults (youth: once diabetes has lasted 3-5 years and age ≥11 or puberty has begun), then every 1-2 years if no retinopathy (contrast T2DM, where the first exam is at diagnosis)Not routine for diagnosis; Dilated retinal exam at diagnosis and annually; Consider liver imaging if AST/ALT elevated (NAFLD evaluation)
First-line treatmentLifelong exogenous insulin — basal-bolus regimen mimicking physiologic secretion; Long-acting basal insulin: glargine (Lantus, Basaglar, Toujeo) or degludec (Tresiba) — once daily; detemir (Levemir) has been removed from the US market; Rapid-acting prandial insulin: lispro (Humalog), aspart (Novolog), glulisine (Apidra) — at meals based…Lifestyle modification: 5-10% weight loss, Mediterranean/DASH diet, 150 min/week moderate aerobic exercise + resistance training, smoking cessation; Biguanide — metformin: first-line for most patients (unless contraindicated); start 500 mg daily, titrate to 1000 mg BID; reduces hepatic gluconeogenesis; weight neutral; low hypoglycemia…

Drill Type 1 Diabetes Mellitus vs Type 2 Diabetes Mellitus questions on FirstPassPA

Turn this comparison into retention. 7,200+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Full outlines

Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus All 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.